Abstract
Angiotensin II (AngII) is a major contributor to the development of heart failure, however, the molecular and cellular mechanisms still remain elucidative. Inadequate angiogenesis in myocardium leads to transition from cardiac hypertrophy to dysfunction, this study was therefore conducted to examine the effects of AngII on myocardial angiogenesis and the underlying mechanisms. AngII treatment significantly impaired angiogenetic responses, which were determined by counting the capillaries either in matrigel formed by cultured cardiac microvascular endothelial cells (CMVECs) or in myocardium of mice and by measuring the in vitro and in vivo production of VEGF proteins, and stimulated accumulation and phosphorylation of cytosolic p53 which led to increases in phosphorylated p53 and decreases of hypoxia inducible factor (Hif-1) in nucleus. All of these cellular and molecular events induced by AngII in CEMCs and hearts of mice were largely reduced by a p53 inhibitor, pifithrin-α (PFT-α). Interestingly, AngII stimulated the upregulation of Jagged1, a ligand of Notch, but it didn't affect the expression of Delta-like 4 (Dll-4), another ligand of Notch. Inhibition of p53 by PFT-α partly abolished this effect of AngII. Further experiments showed that knockdown of Jagged1 by addition of siRNA to cultured CMVECs dramatically declined AngII-stimulated accumulation and phosphorylation of p53 in cytosol, upregulation of phosphorylated p53 and downregulation of Hif-1 expression in nucleus, decrease of VEGF production and impairment of capillary-like tube formation by the cells. Our data collectively suggest that AngII impairs myocardial angiogenetic responses through p53-dependent downregulation of Hif-1 which is regulated by Jagged1/Notch1 signaling.
Introduction
In a healthy heart undergoing stress, such as hypertension, the myocardium undergoes hypertrophy. To sustain this increased muscle mass, the heart must grow new blood vessels through angiogenesis. If angiogenesis fails to keep pace, the heart suffers from oxygen and nutrient deprivation, leading to clinical heart failure. Angiotensin II (AngII) is a hormone central to heart failure development and is known to impair this vital angiogenic response. This study maps the specific signaling pathway connecting AngII to the suppression of myocardial angiogenesis, focusing on the roles of the Notch ligand Jagged1 and the tumor suppressor p53.
Methodology
The researchers employed a dual approach using primary cultured cardiac microvascular endothelial cells (CMVECs) from rats and a mouse model with chronic AngII infusion. Angiogenesis was assessed using capillary-like tube formation assays on Matrigel. Molecular mechanisms were explored using pifithrin-α (PFT-α) to inhibit p53 activity and siRNA to silence Jagged1 expression. Protein levels of p53, Hif-1α, Jagged1, and VEGF were quantified via Western blotting and ELISA, while transcriptional activity was measured using luciferase reporter assays.
Results
AngII treatment significantly reduced the heart's ability to form new vascular structures. Quantitative analysis of CMVECs showed a dramatic decrease in the number of capillary-like tubes formed in the presence of AngII compared to control conditions.
Visual inspection of the Matrigel assays confirmed these findings, with AngII-treated cells failing to form the organized networks seen in the control group.
Molecular analysis revealed that AngII specifically upregulates Jagged1, leading to the accumulation and activation (phosphorylation) of p53. This activated p53 interferes with Hif-1α, the master regulator of pro-angiogenic genes, resulting in reduced VEGF production. Crucially, inhibiting p53 with PFT-α or silencing Jagged1 with siRNA restored Hif-1α levels and rescued the angiogenic impairment even in the presence of AngII.
Discussion and Conclusion
This study establishes a clear signaling hierarchy: AngII → Jagged1/Notch1 → p53 accumulation → Hif-1α suppression → Reduced VEGF → Impaired Angiogenesis. These findings identify Jagged1 and p53 as critical molecular "brakes" applied by AngII to blood vessel growth. While the exact biochemical mechanism by which Notch signaling triggers p53 accumulation requires further study, the results suggest that targeting the Jagged1/p53 axis could offer new therapeutic avenues for treating heart failure. However, given p53's essential role as a tumor suppressor, future clinical interventions would likely require heart-specific delivery mechanisms to minimize systemic risks.
Summary updated